AMERICAN SOCIETY OF CLINICAL ONCOLOGY

MAIA Biotechnology appointed two prominent hepatocellular carcinoma specialists, Dr. Claudia Fulgenzi and Dr. David J. Pinato, to its Scientific Advisory Board to guide upcoming clinical trials.

Patients with relapsed/refractory multiple myeloma from lower socioeconomic backgrounds report significantly worse quality of life and higher prevalence of clinically important symptoms that limit daily activities.

A study of over 1.3 million breast cancer patients found that living in food deserts significantly reduces clinical trial participation rates.

A phase 3 placebo-controlled trial demonstrated that adding 5 mg olanzapine to standard ondansetron therapy significantly reduced radiation-induced nausea and vomiting in patients receiving abdominal/pelvic radiotherapy.

A third of 97 patients with advanced multiple myeloma achieved complete remission lasting five years or more after receiving a single infusion of CAR-T immunotherapy developed by Legend Biotech.

Real-world data from 877 patients and clinical trial data from 702 patients demonstrate that most cytokine release syndrome and neurological events with lisocabtagene maraleucel occur within 15 days of infusion and are not severe.

A comprehensive analysis of 105,000 colorectal cancer patients found that Black, Hispanic, Latino, and American Indian populations are disproportionately represented in early-onset cases diagnosed before age 50.

A discrete choice experiment with 205 ALK+ NSCLC patients and 125 caregivers found that both groups overwhelmingly prioritized 3-year progression-free survival when making treatment decisions.

A multi-center phase 2 clinical trial led by Northwestern Medicine found that Duavee significantly reduced cell growth in breast tissue among 141 postmenopausal women with ductal carcinoma in situ (DCIS).

Five-year follow-up data from the SEQUOIA study demonstrates zanubrutinib's sustained efficacy in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma patients with del(17p).